A study was conducted which, at the endpoint, showed reductions in diastolic blood pressure, liver steatosis, total cholesterol, LDL-c and ALT following 10 days of treatment with TVB-2640, even at a dose of 100 mg per day, in patients with metabolic syndrome. The gene discussed is GPT; the disease is fatty liver disease.